30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Maravai LifeSciences Holdings Inc (MRVI)

Track

Over the last 90 days, Maravai LifeSciences Holdings Inc. has seen insider activity dominated by sales, totaling $635,500. Notably, General Counsel Kurt Oreshack executed multiple planned and proposed sales in June 2026. This contrasts with earlier buying activity in late 2025 by CEO Bernd Brust and other executives. The company's stock has experienced significant positive performance.
Stock chart
Ticker: MRVI Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
ORESHACK KURT
General Counsel
3 sales — total 300,000 USD
Planned sale 10 Jun 2026
Value US$4,921,791.95 | Price 347.43 | Shares 70,567
Planned sale 10 Jun 2026
Value US$4,868,389.62 | Price 249.80 | Shares 15,066
Proposed sale 10 Jun 2026
Value US$100,000.00 | Price 5.10 | Shares 1,000
Planned sale 9 Jun 2026
Value US$4,492,030.17 | Price 182.11 | Shares 76,705
Proposed sale 9 Jun 2026
Value US$240,535.72 | Price 422.61 | Shares 46,744
Proposed sale 23 Dec 2025
Value US$13,138.08 | Price 3.33 | Shares 3,951
Proposed sale 19 Dec 2025
Value US$187,526.04 | Price 3.48 | Shares 53,951
Buy 8 Dec 2025
Value US$178,097.76 | Price 3.67 | Shares 48,528
Buy 5 Dec 2025
Value US$190,446.40 | Price 3.70 | Shares 51,472
Buy 13 Nov 2025
Value US$702,689.00 | Price 3.25 | Shares 216,212
Buy 12 Nov 2025
Value US$299,679.18 | Price 3.21 | Shares 93,358
Buy 11 Nov 2025
Value US$509,331.24 | Price 3.24 | Shares 157,201
Proposed sale 31 Jan 2025
Value US$125,750.00 | Price 5.03 | Shares 25,000
Planned sale 31 Jan 2025
Value US$125,750.00 | Price 5.03 | Shares 25,000
Buy 12 Nov 2024
Value US$100,625.00 | Price 5.75 | Shares 17,500
Buy 11 Nov 2024
Value US$987,000.00 | Price 5.64 | Shares 175,000
Sale 28 May 2024
Value US$97,570,659.81 | Price 9.82 | Shares 9,940,974
Proposed sale 28 May 2024
Value US$16,504,481.84 | Price 10.78 | Shares 1,531,028
Proposed sale 28 May 2024
Value US$90,659,217.88 | Price 10.78 | Shares 8,409,946
Buy 25 Nov 2020
Value US$942,900.00 | Price 26.94 | Shares 35,000
Buy 24 Nov 2020
Value US$509,976.00 | Price 27.00 | Shares 18,888
Buy 24 Nov 2020
Value US$540,000.00 | Price 27.00 | Shares 20,000
Buy 24 Nov 2020
Value US$486,000.00 | Price 27.00 | Shares 18,000
Buy 24 Nov 2020
Value US$270,000.00 | Price 27.00 | Shares 10,000
Buy 24 Nov 2020
Value US$1,350,000.00 | Price 27.00 | Shares 50,000
Buy 24 Nov 2020
Value US$405,000.00 | Price 27.00 | Shares 15,000
Buy 24 Nov 2020
Value US$202,500.00 | Price 27.00 | Shares 7,500
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-10 2026-06-10 PlS Planned sale
3.2
ORESHACK KURT

General Counsel

Officer
70,567 -15.8%
347.43
US$4,921,792 		70,567 -15.8% 347.43 US$4,921,792
2026-06-10 2026-06-10 PlS Planned sale
3.2
ORESHACK KURT

General Counsel

Officer
15,066 +5.8%
249.80
US$4,868,390 		15,066 +5.8% 249.80 US$4,868,390
2026-06-10 2026-06-10 PrS Proposed sale
3.2
ORESHACK KURT

Officer

Officer
94,319
196.15
US$1,490,647 		94,319 196.15 US$1,490,647
2026-06-10 2026-06-09 PlS Planned sale
3.2
ORESHACK KURT

General Counsel

Officer
1,000 -6.5%
5.06
US$100,000 		1,000 -6.5% 5.06 US$100,000
2026-06-09 2026-06-09 PrS Proposed sale
3.2
ORESHACK KURT

Officer

Officer
1,000
5.06
US$100,000 		1,000 5.06 US$100,000
2025-12-23 2025-12-23 PrS Proposed sale
3.2
PRAHALAD MURALI

Former Director

Non-Executive Director
3,951
3.33
US$13,138 		3,951 3.33 US$13,138
2025-12-19 2025-12-19 PrS Proposed sale
3.2
Hopfield Jessica

Former Director

Non-Executive Director
53,951
3.48
US$187,526 		53,951 3.48 US$187,526
2025-12-09 2025-12-08 B Purchase
2.4
LUCIER GREGORY T
Non-Executive Director
48,528 +45.5%
3.67
US$178,098 		48,528 +45.5% 3.67 US$178,098
2025-12-09 2025-12-05 B Purchase
2.4
LUCIER GREGORY T
Non-Executive Director
51,472 +93.4%
3.70
US$190,446 		51,472 +93.4% 3.70 US$190,446
2025-11-17 2025-11-13 B Purchase
2.4
Brust Bernd

Chief Executive Officer

Executive Director
216,212 +86.3%
3.25
US$702,689 		216,212 +86.3% 3.25 US$702,689
2025-11-13 2025-11-12 B Purchase
2.4
Brust Bernd

Chief Executive Officer

Executive Director
93,358 +59.4%
3.21
US$299,679 		93,358 +59.4% 3.21 US$299,679
2025-11-13 2025-11-11 B Purchase
2.4
Brust Bernd

Chief Executive Officer

Executive Director
157,201 +inf%
3.24
US$509,331 		157,201 +inf% 3.24 US$509,331
2025-01-31 2025-01-31 PrS Proposed sale
3.2
ORESHACK KURT

Officer

Officer
25,000
5.03
US$125,750 		25,000 5.03 US$125,750
2025-01-31 2025-01-31 PlS Planned sale
3.2
ORESHACK KURT

General Counsel

Officer
25,000 -13.0%
5.03
US$125,750 		25,000 -13.0% 5.03 US$125,750
2024-11-14 2024-11-12 B Purchase
0.7
DeFord John A
Non-Executive Director
17,500 +33.3%
5.75
US$100,625 		17,500 +33.3% 5.75 US$100,625
2024-11-12 2024-11-11 B Purchase
2.6
HULL CARL

See Remarks

Executive Director
175,000 +inf%
5.64
US$987,000 		175,000 +inf% 5.64 US$987,000
2024-05-30 2024-05-28 S Sale
3.2
GTCR INVESTMENT XI LLC
Non-Executive Director Large shareholder
9,940,974 -33.0%
9.82
US$97,570,660 		9,940,974 -33.0% 9.82 US$97,570,660
2024-05-28 2024-05-28 PrS Proposed sale
Maravai Life Sciences Holdings 2, LLC

Owner
1,531,028
10.78
US$16,504,482 		1,531,028 10.78 US$16,504,482
2024-05-28 2024-05-28 PrS Proposed sale
Maravai Life Sciences Holdings, LLC

Owner
8,409,946
10.78
US$90,659,218 		8,409,946 10.78 US$90,659,218
2020-11-30 2020-11-25 B Purchase
2.6
HULL CARL

Chief Executive Officer

Executive Director
35,000 +inf%
26.94
US$942,900 		35,000 +inf% 26.94 US$942,900
2020-11-25 2020-11-24 B Purchase
3.2
SELLERS LISA

See Remarks

Officer
18,888 +inf%
27.00
US$509,976 		18,888 +inf% 27.00 US$509,976
2020-11-25 2020-11-24 B Purchase
3.2
GRAY SUSANNAH
Non-Executive Director
20,000 +168.7%
27.00
US$540,000 		20,000 +168.7% 27.00 US$540,000
2020-11-25 2020-11-24 B Purchase
3.2
PRAHALAD MURALI
Non-Executive Director
18,000 +151.9%
27.00
US$486,000 		18,000 +151.9% 27.00 US$486,000
2020-11-25 2020-11-24 B Purchase
3.2
Hance Robert B
Non-Executive Director
10,000 +84.4%
27.00
US$270,000 		10,000 +84.4% 27.00 US$270,000
2020-11-25 2020-11-24 B Purchase
3.2
Hopfield Jessica
Non-Executive Director
50,000 +421.9%
27.00
US$1,350,000 		50,000 +421.9% 27.00 US$1,350,000
2020-11-25 2020-11-24 B Purchase
2.4
LUCIER GREGORY T
Non-Executive Director
15,000 +126.6%
27.00
US$405,000 		15,000 +126.6% 27.00 US$405,000
2020-11-25 2020-11-24 B Purchase
3.2
ORESHACK KURT

General Counsel

Officer
7,500 +inf%
27.00
US$202,500 		7,500 +inf% 27.00 US$202,500
Explore more

More insider trading research around Maravai LifeSciences Holdings Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America